

POSTER PRESENTATION

Open Access

Towards targeting PD-1/PD-L1 axis in breast cancer, pre-clinical data

Hazem Ghebeh^{1*}, Dilek Colak², Asma Tullbah³, Abdullah Alsuliman¹

From Breast Cancer Immunotherapy Symposium (BRECIS), part of the Sidra Symposia Series, held in partnership with the Society for Immunotherapy of Cancer Doha, Qatar. 13-14 April 2015

PD-L1 is a ligand that upon binding to its receptor (PD-1) on T-cells leads to T-cell anergy/and or apoptosis [1,2]. We have shown that PD-L1 is expressed in breast cancer where its expression correlates with estrogen receptor (ER) negativity [3]. To understand the mechanism of the constitutive expression of PD-L1 in tumor cells of ER negative cells we used gene-in and out approach, large scale bioinformatics and immunohistochemistry. We have demonstrated that epithelial to mesenchymal transition (EMT) upregulates PD-L1 expression while cells expressing ER downregulates PD-L1, in parallel with reversal of EMT process. Bioinformatics analysis of gene expression signatures of breast tumors showed a significant correlation between EMT score and PD-L1 mRNA expression. Strikingly, very strong association were found between PD-L1 expression and claudin low breast cancer, a subset of breast cancer known to have high EMT score. In conclusion, we have characterized the expression of PD-L1 in breast cancer and we have demonstrated a strong association between PD-L1 expression, EMT status and claudin-Low breast cancer. Our finding will be essential for choosing the appropriate subset of breast cancer patients that will likely benefit from anti-PD-L1 targeted therapy and understand biological changes upon anti-PD-L1 therapy.

Authors' details

¹Stem Cell & Tissue Re-engineering Program, King Faisal Specialist Hospital and Research Centre, Takhassusi Road, Al-Maathar, Riyadh, Saudi Arabia. ²Department of Biostatistics, Epidemiology and Scientific Computing, King Faisal Specialist Hospital & Research, Takhassusi Road, Al-Maathar, Riyadh, Saudi Arab. ³Department of Pathology and Laboratory Medicine, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arab.

¹Stem Cell & Tissue Re-engineering Program, King Faisal Specialist Hospital and Research Centre, Takhassusi Road, Al-Maathar, Riyadh, Saudi Arabia
Full list of author information is available at the end of the article



© 2015 Ghebeh et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated.

Published: 14 August 2015

References

1. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne MC, et al: Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. *J Exp Med* 2000, **192**(7):1027-1034.
2. Selenko-Gebauer N, Majdic O, Szekeres A, Hofler G, Guthann E, Korthauer U, Zlabinger G, Steinberger P, Pickl WF, Stockinger H, et al: B7-H1 (programmed death-1 ligand) on dendritic cells is involved in the induction and maintenance of T cell anergy. *J Immunol* 2003, **170**(7):3637-3644.
3. Ghebeh H, Mohammed S, Al-Omair A, Qattan A, Lehe C, Al-Qudaihi G, Elkum N, Alshabanah M, Amer Bin S, Tullbah A, et al: The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. *Neoplasia* 2006, **8**(3):190-198.

doi:10.1186/2051-1426-3-S1-P7

Cite this article as: Ghebeh et al.: Towards targeting PD-1/PD-L1 axis in breast cancer, pre-clinical data. *Journal for ImmunoTherapy of Cancer* 2015 **3**(Suppl 1):P7.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

